Biorealm Biopharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 252.99%
- Profit Growth 4.30%
- Ebitda 79.49%
- Net Worth 74.26%
- Total Assets 45.85%
About Biorealm Biopharmaceuticals
Biorealm Biopharmaceuticals Private Limited (BBPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 December 2013 and has a history of 11 years and two months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bhanwarlal Choudhary, Neeraj Kumar, and Suneeta Devi serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299MH2013PTC250679
- Company No.
250679
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Biorealm Biopharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhanwarlal Choudhary  | Director | 03-Dec-2013 | Current |
| Neeraj Kumar | Director | 03-Dec-2013 | Current |
| Suneeta Devi | Director | 25-Apr-2022 | Current |
Financial Performance of Biorealm Biopharmaceuticals.
Biorealm Biopharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 252.99% increase. The company also saw a slight improvement in profitability, with a 4.3% increase in profit. The company's net worth Soared by an impressive increase of 74.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biorealm Biopharmaceuticals?
In 2023, Biorealm Biopharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hippocrat Biotech Private LimitedNeeraj Kumar and Suneeta Devi are mutual person
- Hippocrat Dialysis Services Private Limited
Neeraj Kumar and Suneeta Devi are mutual person
- Hippocrat Biomedical Llp
Neeraj Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biorealm Biopharmaceuticals?
Unlock and access historical data on people associated with Biorealm Biopharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biorealm Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biorealm Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
